Table 2.
The relationship between inflammatory indices and other variables.
| NLR | PNI | SII | |||||||
|---|---|---|---|---|---|---|---|---|---|
| <2.57 | ≥2.57 | p-value | <37.7 | ≥37.7 | p-value | <799.5 | ≥799.5 | p-value | |
| Age – <65 years – ≥65 years |
12 (92.3) 1 (7.7) |
12 (48.0) 13 (52.0) |
0.012 |
13 (61.9) 8 (38.1) |
11 (64.7) 6 (35.3) |
0.859 |
11 (78.6) 3 (21.4) |
13 (54.2) 11 (45.8) |
0.132 |
| Sex – Women – Men |
11 (84.6) 2 (15.4) |
10 (40.0) 15 (60.0) |
0.009 |
14 (66.7) 7 (33.3) |
7 (41.2) 10 (58.8) |
0.116 |
11 (78.6) 3 (21.4) |
10 (41.7) 14 (58.3) |
0.027 |
| ECOG – 0 – 1 – 2 – 3 |
1 (7.7) 8 (61.5) 4 (30.8) 0 (0.0) |
2 (8.0) 15 (60.0) 6 (24.0) 2 (8.0) |
0.935 |
1 (4.8) 11 (52.4) 7 (33.3) 2 (9.5) |
2 (11.8) 12 (70.6) 3 (17.6) 0 (0.0) |
0.387 |
1 (7.1) 9 (64.3) 4 (28.6) 0 (0.0) |
2 (8.3) 14 (58.3) 6 (25.0) 2 (8.3) |
0.875 |
| Smoking – No – Yes |
11 (84.6) 2 (15.4) |
13 (54.2) 11 (45.8) |
0.083 |
14 (70.0) 6 (30.0) |
10 (58.8) 7 (41.2) |
0.478 |
12 (85.7) 2 (14.3) |
12 (52.2) 11 (47.8) |
0.074 |
| Comorbidity – No – Yes |
9 (69.2) 4 (30.8) |
17 (73.9) 6 (26.1) |
1.000 |
14 (70.0) 6 (30.0) |
12 (75.0) 4 (25.0) |
>0.999 |
10 (76.9) 3 (23.1) |
16 (69.6) 7 (30.4) |
0.716 |
| Mutation – EGFR – ALK – ROS – BRAF |
4 (30.8) 7 (53.8) 2 (15.4) 0 (0.0) |
19 (76.0) 5 (20.0) 0 (0.0) 1 (4.0) |
0.005 |
11 (52.4) 9 (42.9) 0 (0.0) 1 (4.8) |
12 (70.6) 3 (17.6) 2 (11.8) 0 (0.0) |
0.099 |
5 (35.7) 7 (50.0) 2 (14.3) 0 (0.0) |
18 (75.0) 5 (20.8) 0 (0.0) 1 (4.2) |
0.015 |
| Which series – First line – Seond line and after |
8 (61.5) 5 (38.5) |
11 (44.0) 14 (56.0) |
0.305 |
12 (57.1) 9 (42.9) |
7 (41.2) 10 (58.8) |
0.328 |
9 (64.3) 5 (35.7) |
10 (41.7) 14 (58.3) |
0.179 |
| Metastasis site in diagnosis – Lung – Brain – Bone – Surrenal – Multiple |
10 (76.9) 1 (7.7) 2 (15.4) 0 (0.0) 0 (0.0) |
3 (12.5) 6 (25.0) 10 (41.7) 3 (12.5) 2 (8.3) |
0.002 |
8 (40.0) 5 (25.0) 2 (10.0) 3 (15.0) 2 (10.0) |
5 (29.4) 2 (11.8) 10 (58.8) 0 (0.0) 0 (0.0) |
0.011 |
10 (71.4) 1 (7.1) 3 (21.4) 0 (0.0) 0 (0.0) |
3 (13.0) 6 (26.1) 9 (39.1) 3 (13.0) 2 (8.7) |
0.006 |
| Brain metastases on follow-up – No – Yes |
11 (84.6) 2 (15.4) |
18 (75.0) 6 (25.0) |
0.685 |
17 (81.0) 4 (19.0) |
12 (75.0) 4 (25.0) |
0.705 |
11 (78.6) 3 (21.4) |
18 (78.3) 5 (21.7) |
1.000 |
| Progression – No – Yes |
4 (30.8) 9 (69.2) |
2 (8.0) 23 (92.0) |
0.154 |
2 (9.5) 19 (90.5) |
4 (23.5) 13 (76.5) |
0.378 |
5 (35.7) 9 (64.3) |
1 (4.2) 23 (95.8) |
0.018 |
| Latest status – Live – Exitus |
5 (38.5) 8 (61.5) |
3 (12.0) 22 (88.0) |
0.094 |
3 (14.3) 18 (85.7) |
5 (29.4) 12 (70.6) |
0.426 |
5 (35.7) 9 (64.3) |
3 (12.5) 21 (87.5) |
0.117 |
Bold p-values indicate they are statistically significant.
ECOG: Eastern Cooperative Oncology Group; NLR: Neutrophil–lymphocyte ratio; PNI: Prognostic nutritional index; SII: Systemic immune-inflammation index.